The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

SABCS 2019 Highlights on IO in mTNB: IMpassion130 Suggest PD-L1+ Pts Have Better Outcomes w/ Atezolizumab+Chemo, SAFIRO2-IMMUNO Suggests Durvalumab Improves OS

0 views
March 12, 2020
Comments 0
Login to view comments. Click here to Login